# Neuromyelitis Optica Spectrum Disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder

> 2 upcoming FDA catalysts in neuromyelitis Optica Spectrum Disorder: UPLIZNA® (inebilizumab, AMGN) on Apr to Jul 2027 (topline data readout); UPLIZNA® (inebilizumab, AMGN) on April 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Neuromyelitis Optica Spectrum Disorder | delayed | "NCT05346354 (Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-06-22 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05346354)) |
| Apr to Jul 2027 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549258)) |
| April 2027 | [UPLIZNA® (inebilizumab) primary completion](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549258)) |

## Drugs

- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [UPLIZNA® (inebilizumab)](https://sec-api.dev/pdufa/inebilizumab) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Neuromyelitis Optica Spectrum Disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder

```bibtex
@misc{secapidev_indications_neuromyelitis_optica_spectrum_disorder_20261116,
  title        = {Neuromyelitis Optica Spectrum Disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_neuromyelitis_optica_spectrum_disorder_20261116","title":"Neuromyelitis Optica Spectrum Disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
